You are here: Home » Markets » News
Business Standard

Pharma shares gain; Sun Pharma hits seven-month high

Wockhadrt, Biocon, Ipca Laboratories, Glenmark Pharmaceuticals, Lupin and Cadila Healthcare were up more than 2% on the National Stock Exchange.

SI Reporter  |  Mumbai 

If implemented, the Draft Pharmaceutical Policy, 2017, will disrupt the Indian drug industry in fundamental ways

Shares of pharmaceutical companies were in focus with most of the frontline stocks trading higher in the range of 2% to 8% on BSE.

Sun Pharmaceutical Industries, Wockhadrt, Biocon, Ipca Laboratories, Glenmark Pharmaceuticals, and Cadila Healthcare were up more than 2% on the National Stock Exchange (NSE).

At 09:50 AM; index, the largest gainer among sectoral indices, was up 2.3% at 9,927, as compared to 0.53% rise in the Nifty 50 index. The pharma index hits two-month high of 9,939 in intra-day trade so far.

Among the individual stocks, was up 4% at Rs 605, hits seven month high on the NSE. The stock was trading at its highest level since May 25, 2017 after media reports suggested that the US Food and Drug Administration (USFDA) is expected to begin inspection of manufacturing facility at Halol in the second week of February.

In past two weeks, the stock of has outperformed the market by gaining 12% after the company on December 27 said that the accepted its application for a novel medicine to treat dry-eye disease.

has outperformed vs. large cap peers in the last 6 months despite the large earnings disappointment in FY18 so far. We like Sun Pharma’s specialty strategy for long-term growth. However, at current valuations of the US business, the stock is pricing in the recovery in earnings trajectory from potential clearance in Halol’s status and successful execution of its Specialty pipeline over the next 5 years,” analyst at JP Morgan said in pharma sector update.

The brokerage firm believes there is risk to Sun Pharma’s consensus earnings given FY19 margin assumes strong launch pipeline post Halol, lower erosion in Taro and limited investment in the specialty business. Further, there is also the risk from failure or delay in the specialty pipeline, which is not factored in the current premium valuations.

While the issues in the US generic industry are likely to persist into 2018, analyst believe FDA’s efforts towards faster approvals particularly limited-competition drugs should provide upside for pharmaceutical companies from 2HCY18.

WOCKHARDT 1010.00 936.95 7.8
SUN PHARMA.INDS. 602.35 578.75 4.1
SYNGENE INTL. 594.95 572.15 4.0
MARKSANS PHARMA 43.30 41.85 3.5
BIOCON 558.10 541.20 3.1
LUPIN 923.45 899.15 2.7
CADILA HEALTH. 452.05 440.45 2.6
GLENMARK PHARMA. 607.00 592.45 2.5
IPCA LABS. 596.05 582.85 2.3
GLAXOSMI. PHARMA 2533.00 2478.95 2.2
DIVI'S LAB. 1127.00 1105.15 2.0
NATCO PHARMA 1018.55 998.90 2.0
STRIDES SHASUN 830.35 817.85 1.5
UNICHEM LABS. 356.50 351.55 1.4
J B CHEM & PHARM 333.00 328.40 1.4
AUROBINDO PHARMA 680.35 671.10 1.4
SHILPA MEDICARE 615.00 607.15 1.3
DR REDDY'S LABS 2499.00 2467.35 1.3
SUVEN LIFE SCIE. 217.80 215.10 1.3
CIPLA 620.40 613.00 1.2

First Published: Mon, January 08 2018. 10:36 IST